Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of a family of proteases that is thought to promote the degradation of the low density lipoprotein receptor (LDLR) through an as yet undefined mechanism. We developed second generation antisense oligonucleotide (ASO) inhibitors target...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2007-04-01
|
| Series: | Journal of Lipid Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0022227520434297 |
| _version_ | 1818671444423344128 |
|---|---|
| author | Mark J. Graham Kristina M. Lemonidis Charles P. Whipple Amuthakannan Subramaniam Brett P. Monia Stanley T. Crooke Rosanne M. Crooke |
| author_facet | Mark J. Graham Kristina M. Lemonidis Charles P. Whipple Amuthakannan Subramaniam Brett P. Monia Stanley T. Crooke Rosanne M. Crooke |
| author_sort | Mark J. Graham |
| collection | DOAJ |
| description | Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of a family of proteases that is thought to promote the degradation of the low density lipoprotein receptor (LDLR) through an as yet undefined mechanism. We developed second generation antisense oligonucleotide (ASO) inhibitors targeting murine PCSK9 to determine their potential as lipid-lowering agents. Administration of a PCSK9 ASO to high fat-fed mice for 6 weeks reduced total cholesterol and LDL by 53% and 38%, respectively. Moreover, inhibition of PCSK9 expression resulted in a 2-fold increase in hepatic LDLR protein levels. This phenotype closely resembles that reported previously in Pcsk9-deficient mice. The absence of cholesterol lowering in Ldlr-deficient mice effectively demonstrated a critical role for this receptor in mediating the lipid-lowering effects of PCSK9 inhibition. Antisense inhibition of PCSK9 is an attractive and novel therapeutic approach for treating hypercholesterolemia in human. |
| first_indexed | 2024-12-17T07:24:06Z |
| format | Article |
| id | doaj.art-de73d8692cae40cd8902c9742360e4eb |
| institution | Directory Open Access Journal |
| issn | 0022-2275 |
| language | English |
| last_indexed | 2024-12-17T07:24:06Z |
| publishDate | 2007-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Lipid Research |
| spelling | doaj.art-de73d8692cae40cd8902c9742360e4eb2022-12-21T21:58:41ZengElsevierJournal of Lipid Research0022-22752007-04-01484763767Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic miceMark J. Graham0Kristina M. Lemonidis1Charles P. Whipple2Amuthakannan Subramaniam3Brett P. Monia4Stanley T. Crooke5Rosanne M. Crooke6Cardiovascular Group, Department of Antisense Drug Discovery, Isis Pharmaceuticals, Inc., Carlsbad, CA 92008Cardiovascular Group, Department of Antisense Drug Discovery, Isis Pharmaceuticals, Inc., Carlsbad, CA 92008Cardiovascular Group, Department of Antisense Drug Discovery, Isis Pharmaceuticals, Inc., Carlsbad, CA 92008Cardiovascular Group, Department of Antisense Drug Discovery, Isis Pharmaceuticals, Inc., Carlsbad, CA 92008Cardiovascular Group, Department of Antisense Drug Discovery, Isis Pharmaceuticals, Inc., Carlsbad, CA 92008Cardiovascular Group, Department of Antisense Drug Discovery, Isis Pharmaceuticals, Inc., Carlsbad, CA 92008Cardiovascular Group, Department of Antisense Drug Discovery, Isis Pharmaceuticals, Inc., Carlsbad, CA 92008Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of a family of proteases that is thought to promote the degradation of the low density lipoprotein receptor (LDLR) through an as yet undefined mechanism. We developed second generation antisense oligonucleotide (ASO) inhibitors targeting murine PCSK9 to determine their potential as lipid-lowering agents. Administration of a PCSK9 ASO to high fat-fed mice for 6 weeks reduced total cholesterol and LDL by 53% and 38%, respectively. Moreover, inhibition of PCSK9 expression resulted in a 2-fold increase in hepatic LDLR protein levels. This phenotype closely resembles that reported previously in Pcsk9-deficient mice. The absence of cholesterol lowering in Ldlr-deficient mice effectively demonstrated a critical role for this receptor in mediating the lipid-lowering effects of PCSK9 inhibition. Antisense inhibition of PCSK9 is an attractive and novel therapeutic approach for treating hypercholesterolemia in human.http://www.sciencedirect.com/science/article/pii/S0022227520434297antisense oligonucleotideslow density lipoprotein receptorhyperlipidemia |
| spellingShingle | Mark J. Graham Kristina M. Lemonidis Charles P. Whipple Amuthakannan Subramaniam Brett P. Monia Stanley T. Crooke Rosanne M. Crooke Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice Journal of Lipid Research antisense oligonucleotides low density lipoprotein receptor hyperlipidemia |
| title | Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice |
| title_full | Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice |
| title_fullStr | Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice |
| title_full_unstemmed | Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice |
| title_short | Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice |
| title_sort | antisense inhibition of proprotein convertase subtilisin kexin type 9 reduces serum ldl in hyperlipidemic mice |
| topic | antisense oligonucleotides low density lipoprotein receptor hyperlipidemia |
| url | http://www.sciencedirect.com/science/article/pii/S0022227520434297 |
| work_keys_str_mv | AT markjgraham antisenseinhibitionofproproteinconvertasesubtilisinkexintype9reducesserumldlinhyperlipidemicmice AT kristinamlemonidis antisenseinhibitionofproproteinconvertasesubtilisinkexintype9reducesserumldlinhyperlipidemicmice AT charlespwhipple antisenseinhibitionofproproteinconvertasesubtilisinkexintype9reducesserumldlinhyperlipidemicmice AT amuthakannansubramaniam antisenseinhibitionofproproteinconvertasesubtilisinkexintype9reducesserumldlinhyperlipidemicmice AT brettpmonia antisenseinhibitionofproproteinconvertasesubtilisinkexintype9reducesserumldlinhyperlipidemicmice AT stanleytcrooke antisenseinhibitionofproproteinconvertasesubtilisinkexintype9reducesserumldlinhyperlipidemicmice AT rosannemcrooke antisenseinhibitionofproproteinconvertasesubtilisinkexintype9reducesserumldlinhyperlipidemicmice |